Background N-methyl-D-aspartate (NMDA) receptor activation requires the binding of a co-
agonist on the glycine-binding site. D-serine is the main endogenous co-agonist of NMDA …

Deficits in N-methyl-d-aspartate receptor (NMDAR) function are increasingly linked to
persistent negative symptoms and cognitive deficits in schizophrenia. Accordingly, clinical …

N‐methyl‐d‐aspartate receptor (NMDAR) activation can initiate changes in synaptic
strength, evident as long‐term potentiation (LTP), and is a key molecular correlate of …

Activation of the N-methyl-d-aspartate receptor (NMDAR) glycine site has been shown to
accelerate adaptive forms of learning that may benefit psychopathologies involving cognitive …

A common strategy when searching for cognitive‐enhancing drugs has been to target the N‐
methyl‐d‐aspartate receptor (NMDAR), given its putative role in synaptic plasticity and …

Observations that N-Methyl-d-Aspartate (NMDA) antagonists produce symptoms in humans
that are similar to those seen in schizophrenia have led to the current hypothesis that …

Abstract d‐amino acid oxidase (DAO, DAAO) is an enzyme that degrades d‐serine, the
primary endogenous co‐agonist of the synaptic N‐methyl‐d‐aspartate receptor. Convergent …

Multiple studies indicate that N-methyl-d-aspartate (NMDA) receptor hypofunction underlies
some of the deficits associated with schizophrenia. One approach for improving NMDA …

We characterized the mechanism and pharmacodynamics of five structurally distinct
inhibitors of d-amino acid oxidase. All inhibitors bound the oxidized form of human enzyme …

The effects of the N-methyl-D-aspartate receptor activators D-serine, D-alanine, and
sarcosine against schizophrenia and depression are promising. Nevertheless, high doses of …